News Sentiment

LIMN sentiment intelligence

Liminatus Pharma, Inc. Class A Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.12 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+7.5% over one week, +3.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Enterprise value to EBITDA forward of Liminatus Pharma, Inc. – BOATS:LIMNW

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 7.5% Price confirming higher
Trend fit Trend inactive 3.2% over four weeks
Fair value -95.5% Below fair value
Market Dynamics buy signal Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 40
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 10
Market source 9
Stock Titan 9
Investing.com Nigeria 6
Benzinga 3
Moomoo 2
GlobeNewswire 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 17
Deals and strategy 11
Regulatory and legal 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 63
TradingView Direct company coverage

Enterprise value to EBITDA forward of Liminatus Pharma, Inc. – BOATS:LIMNW

This article provides financial information for Liminatus Pharma, Inc. (LIMNW) on TradingView, specifically focusing on its enterprise value to EBITDA forward. It indicates that no trades have occurred and the market is closed for this stock. The page is primarily a financial dat

Tone
Neutral 50/100
Event
Market update
Published
19 Jul 2026 10:43
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Liminatus Pharma, Inc. – BOATS:LIMNW

The article mentions the "Price to earnings forward" for Liminatus Pharma, Inc. (BOATS:LIMNW) and indicates that the market is currently closed with no trades. It appears to be a financial data snippet from a trading platform, potentially TradingView, listing basic company and ma

Tone
Neutral 50/100
Event
Earnings
Published
18 Jul 2026 17:39
Source
TradingView
Benzinga Direct company coverage

12 Health Care Stocks Moving In Thursday's Intraday Session

This article identifies 12 health care stocks that experienced significant price movements during Thursday's intraday trading session. It highlights both gainers, such as Liminatus Pharma and Agape ATP, and decliners, including Alpha Compute and Senti Biosciences, detailing their

Tone
Positive 70/100
Event
Market update
Published
16 Jul 2026 16:41
Source
Benzinga
Sahm Direct company coverage

Liminatus Pharma (LIMN) Stock Is Trending Overnight — Here’s Why it Spiked Over 30% in After-Hours Session

Liminatus Pharma (LIMN) stock surged over 30% in after-hours trading following an amendment to its merger agreement with InnocsAI LLC. The revised structure allows the deal to close quickly, with InnocsAI equity holders receiving a combination of Liminatus common and non-voting c

Tone
Positive 66/100
Event
Deals and strategy
Published
15 Jul 2026 20:43
Source
Sahm
Investing.com Nigeria Direct company coverage

Form 13D/A Liminatus Pharma For: 14 July By Investing.com

This article announces the filing of Form 13D/A for Liminatus Pharma on July 14, indicating a significant disclosure related to the company. It briefly mentions the stock symbol LIMN and its price performance, but provides no further details on the content of the filing itself. T

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 10:12
Source
Investing.com Nigeria
Investing.com Nigeria Direct company coverage

Form 4 Liminatus Pharma Inc For: 14 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Liminatus Pharma Inc, dated July 14, 2026. Form 4 filings are used to report changes in beneficial ownership of securities by company insiders. The article indicates that Liminatus Pharma Inc (LIMN) saw a 15.36% incre

Tone
Positive 60/100
Event
Market update
Published
14 Jul 2026 22:52
Source
Investing.com Nigeria
Investing.com Nigeria Direct company coverage

Form DEF 14A Liminatus Pharma Inc For: 13 July By Investing.com

This article reports on the filing of Form DEF 14A by Liminatus Pharma Inc. on July 13th, as published by Investing.com. It indicates Liminatus Pharma Inc. (LIMN) stock is down 8.30%. The content is brief, primarily acting as an announcement of the regulatory filing and its date.

Tone
Negative 31/100
Event
Regulatory and legal
Published
13 Jul 2026 13:50
Source
Investing.com Nigeria
TradingView Direct company coverage

Price to sales forward of Liminatus Pharma, Inc. – NASDAQ:LIMNW

The article displays the "Price to sales forward" metric for Liminatus Pharma, Inc. (NASDAQ: LIMNW) within the TradingView platform. It shows that there are no trades and the market is closed for this specific financial metric. The content highlights the navigation path to this i

Tone
Neutral 50/100
Event
Market update
Published
12 Jul 2026 13:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Liminatus Pharma, Inc. – NASDAQ:LIMN

The article displays the "Price to sales forward" metric for Liminatus Pharma, Inc. (LIMN) on the Nasdaq Stock Market. It indicates that the market was closed at the time of viewing, with no trades observed. The content primarily shows the financial information section for the co

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 23:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Liminatus Pharma, Inc. – NASDAQ:LIMN

This article focuses on the enterprise value to EBIT forward metric for Liminatus Pharma, Inc. (NASDAQ: LIMN). It appears to be a financial data point provided on a trading platform, likely TradingView, indicating a specific financial ratio for the company's valuation.

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:13
Source
TradingView
Kalkine Direct company coverage

Liminatus Pharma, Inc. Class A Common Stock (NASDAQ: LIMN) Stock Price, News & Analysis

This article provides an overview of Liminatus Pharma, Inc. (NASDAQ: LIMN) stock, including its current price, basic fundamental data, and a link to charting information. It highlights the stock's last updated price of $0.123 and discusses its low trading volume. The page also of

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:13
Source
Kalkine
TradingView Direct company coverage

Number of employees of Liminatus Pharma, Inc. – NASDAQ:LIMNW

This article focuses on Liminatus Pharma, Inc. (NASDAQ: LIMNW) and specifically addresses the number of its employees. It appears to be a stub or data-point-oriented page from TradingView, which aggregates financial data for the company.

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 13:11
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Liminatus Pharma, Inc. – NASDAQ:LIMN

This article provides financial data for Liminatus Pharma, Inc. (NASDAQ: LIMN), focusing on its enterprise value to EBITDA forward metric. The content highlights the company's stock market information on Nasdaq and lists various financial and community services offered by Trading

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 01:10
Source
TradingView
Stock Titan Direct company coverage

4.37M Liminatus (NASDAQ: LIMN) shares moved in entity transfer

Valetudo Therapeutics LLC, a ten percent owner of Liminatus Pharma (NASDAQ: LIMN) and associated with CEO Chris Kim, transferred 4,373,603 shares of common stock to Ewon Comfortech Co., Ltd. for no consideration. Valetudo retains voting power over these transferred shares through

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 17:11
Source
Stock Titan
Stock Titan Direct company coverage

Ewon Comfortech discloses 5.5M shares in Liminatus Pharma (NASDAQ: LIMN)

Ewon Comfortech Co., Ltd. has disclosed a beneficial ownership of 5.5 million shares, representing 10.9% of Liminatus Pharma Inc. (NASDAQ: LIMN) common stock, according to a Schedule 13G/A filing. The filing indicates Ewon Comfortech holds sole dispositive power over all 5.5 mill

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 05:10
Source
Stock Titan
Stock Titan Direct company coverage

Liminatus Pharma (LIMN) completes InnocsAI acquisition with large convertible preferred stake

Liminatus Pharma has completed its acquisition of InnocsAI by restructuring the merger consideration to include both common stock and a significant stake in new Series A Non-Voting Convertible Preferred Stock. This strategy allowed the deal to close before obtaining full stockhol

Tone
Negative 33/100
Event
Deals and strategy
Published
07 Jul 2026 05:10
Source
Stock Titan
TradingView Direct company coverage

Price to earnings forward of Liminatus Pharma, Inc. – NASDAQ:LIMN

This article provides the "Price to earnings forward" value for Liminatus Pharma, Inc. (NASDAQ: LIMN). It indicates that the value is currently not available, with no trades recorded. The content seems to be a placeholder or a very early stage financial data page for the company

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 03:40
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 4 Liminatus Pharma Inc For: 6 July By Investing.com

This article reports on a Form 4 filing for Liminatus Pharma Inc which took place on July 6th. Form 4 filings are regulatory documents that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders

Tone
Negative 29/100
Event
Regulatory and legal
Published
06 Jul 2026 22:04
Source
Investing.com Nigeria
Finviz Direct company coverage

LIMN - Liminatus Pharma Inc Options

This article provides a detailed financial overview of Liminatus Pharma Inc. (LIMN), including its market capitalization, income, sales, key valuation ratios, and stock performance metrics. It covers various operational and financial statistics, such as insider and institutional

Tone
Positive 59/100
Event
Market update
Published
04 Jul 2026 04:09
Source
Finviz
RTTNews Direct company coverage

Biotech Pre-Market Pulse: LIMN, TENX, ELTX Swing Big

Several biotech companies are showing significant gains in pre-market trading, indicating early momentum for the day. Liminatus Pharma (LIMN), Tenax Therapeutics (TENX), and Conexeu Sciences (CNXU) are among the leading gainers. The article details the top 10 pre-market biotech s

Tone
Positive 69/100
Event
Market update
Published
02 Jul 2026 13:41
Source
RTTNews
Benzinga Direct company coverage

12 Health Care Stocks Moving In Thursday's Pre-Market Session

This article lists 12 healthcare stocks experiencing significant movement in Thursday's pre-market session. It details both gainers like Liminatus Pharma (NASDAQ:LIMN) and Stablecoin Development (AMEX:SDEV), and decliners such as Elicio Therapeutics (NASDAQ:ELTX) and Beyond Air (

Tone
Positive 74/100
Event
Market update
Published
02 Jul 2026 11:41
Source
Benzinga
Moomoo Direct company coverage

Press Release: Liminatus Pharma Amends Definitive Merger Agreement With InnocsAI to Expand Oncology Cell Therapy Pipeline

Liminatus Pharma has amended its definitive merger agreement with InnocsAI, acquiring an exclusive global license for InnocsAI's AI-driven oncology cell therapy programs. This strategic move is expected to expand Liminatus's pipeline, particularly in areas like breast cancer and

Tone
Neutral 50/100
Event
Deals and strategy
Published
01 Jul 2026 14:41
Source
Moomoo